Pharma Mar SA · BME:PHM

Pharma Mar SA — Zeltia — FY2009 Earnings Presentation

8 slides from Pharma Mar SA's earnings presentation, Feb 25, 2010

  1. Slide 1: Full Year 2009 Results Presentation

    Full Year 2009 Results Presentation February 25, 2010 1 Disclaimer This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-looking statements" and are based on the Company's current exp

  2. Slide 2: Operational Overview

    Operational Overview Key Operational Highlights Yondelis® (Oncology): – Nov 2009: European Commission grants Yondelis approval for use in ovarian cancer – Mar 2009: TAIHO Labs granted license for the development and sale of Yondelis® for Japan – Currently approved in 19 countries outside of Europe a

  3. Slide 3: Financial Overview

    Financial Overview Key Financial Highlights Net sales by segment €m Group sales increased by 17.2% y-o-y 80 74.1 70.8 0.7% 71.2 70 to €123.4m: 60 51.33 – Biopharmaceutical segment: 53.3% 50 40 33.7 – Consumer Chemicals segment: 0.7% 30 53.3% 20 Group EBITDA increased by 48.3% y-o- 10 10 y to -€16.1m

  4. Slide 4: Gross Income, Group Debt and Cash Positions

    Increasing Gross Income €m 100 20% 2008 79.4 80 66.2 60 44% 56% 40 20 0 2008 2009 Consumer Chemicals Biopharmaceutical Gross Income Group gross income increased by 20% y- o-y to €79.4m: 2009 – Biopharmaceutical segment contributed 54% compared to 44% in 2008 54% 46% – Consumer chemicals segment cont

  5. Slide 5: Outlook

    Outlook Goals and Objectives • Launch phase III trial for Aplidin® in Multiple Oncology Myeloma and Myelofibrosis Central • Launching phase IIb trial in NYPTA® for the Nervous treatment of Alzheimer’s disease System • Maintain reduction in average monthly cash burn rate Financial • Continue the tren

  6. Slide 6: Questions

    4Zettia Questions

  7. Slide 7: Las ventas del sector biofarmacéutico crecen un 53,3%

    LAS VENTAS DEL SECTOR BIOFARMACEUTICO CRECEN UN 53,3% EL EBITDA MEJORA POR SEGUNDO AÑO CONSECUTIVO Las ventas consolidadas del Grupo ascienden a 123,4 millones de euros a fin del año 2009, frente a 105,3 millones de euros en 2008. El resultado neto mejora un 36,3% y el EBITDA un 48,3%. Madrid, 25 de

  8. Slide 8: neurodegenerativas del Sistema Nervioso Central; Genómica, primera compañía española en el campo del diagnóstico

    neurodegenerativas del Sistema Nervioso Central; Genómica, primera compañía española en el campo del diagnóstico molecular; Sylentis, dedicada a la investigación de las aplicaciones terapéuticas del silenciamiento génico (RNAi), y un sector químico compuesto por Zelnova y Xylazel, dos compañías alta

Zeltia — FY2009 Earnings Presentation on 6ix